Sophiris Bio (SPHS) Reports Q1 Loss of $0.13/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights
May 16, 2016 4:01 PM EDTSAN DIEGO and VANCOUVER, British Columbia, May 16, 2016 /PRNewswire/ --Â Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three months ended March 31, 2016.
Business Highlights:
On May 12, 2016, the Company announced the engagement Oppenheimer & Co. Inc. as its financial advisor to assist with the evaluation of various strategic alternatives. On May 11, 2016, the Company announced the closing of a public offering of common shares and warrants in which the... More